416 related articles for article (PubMed ID: 17377504)
21. Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy.
Kosmadakis G; Filiopoulos V; Smirloglou D; Skarlas P; Georgoulias C; Michail S
Ren Fail; 2010 Jun; 32(5):566-71. PubMed ID: 20486839
[TBL] [Abstract][Full Text] [Related]
22. Cyclosporin A treatment for idiopathic membranous nephropathy.
Yao X; Chen H; Wang Q; Tang Z; Hu W; Yin G; Liu Z; Li L
Chin Med J (Engl); 2001 Dec; 114(12):1305-8. PubMed ID: 11793859
[TBL] [Abstract][Full Text] [Related]
23. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
Hofstra JM; Branten AJ; Wirtz JJ; Noordzij TC; du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
[TBL] [Abstract][Full Text] [Related]
24. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study.
Ballarin J; Poveda R; Ara J; Pérez L; Calero F; Grinyó JM; Romero R
Nephrol Dial Transplant; 2007 Nov; 22(11):3196-201. PubMed ID: 17595183
[TBL] [Abstract][Full Text] [Related]
25. Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial.
Nikolopoulou A; Condon M; Turner-Stokes T; Cook HT; Duncan N; Galliford JW; Levy JB; Lightstone L; Pusey CD; Roufosse C; Cairns TD; Griffith ME
BMC Nephrol; 2019 Sep; 20(1):352. PubMed ID: 31492152
[TBL] [Abstract][Full Text] [Related]
26. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
[TBL] [Abstract][Full Text] [Related]
27. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
28. Electron-Dense Deposition Patterns and the Outcomes of Nephrotic Idiopathic Membranous Nephropathy Treated with Tacrolimus in Chinese Adults.
Xiang X; Feng Z; Jiang Q; Huang D; Meng Z; Luo Z
Med Sci Monit; 2021 Apr; 27():e930500. PubMed ID: 33896931
[TBL] [Abstract][Full Text] [Related]
29. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
Fernández-Juárez G; Rojas-Rivera J; Logt AV; Justino J; Sevillano A; Caravaca-Fontán F; Ávila A; Rabasco C; Cabello V; Varela A; Díez M; Martín-Reyes G; Diezhandino MG; Quintana LF; Agraz I; Gómez-Martino JR; Cao M; Rodríguez-Moreno A; Rivas B; Galeano C; Bonet J; Romera A; Shabaka A; Plaisier E; Espinosa M; Egido J; Segarra A; Lambeau G; Ronco P; Wetzels J; Praga M;
Kidney Int; 2021 Apr; 99(4):986-998. PubMed ID: 33166580
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
Gong L; Xu M; Xu W; Tang W; Lu J; Jiang W; Xie F; Ding L; Qian X
Medicine (Baltimore); 2021 Jul; 100(28):e26628. PubMed ID: 34260552
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
32. Tacrolimus in resistant primary membranous nephropathy--a report of 3 cases.
Szeto CC; Leung CB; Lai FM; Li PK
Clin Nephrol; 2003 Apr; 59(4):293-6. PubMed ID: 12708570
[TBL] [Abstract][Full Text] [Related]
33. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome.
Alexopoulos E; Papagianni A; Tsamelashvili M; Leontsini M; Memmos D
Nephrol Dial Transplant; 2006 Nov; 21(11):3127-32. PubMed ID: 16968719
[TBL] [Abstract][Full Text] [Related]
34. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy.
Torres A; Domínguez-Gil B; Carreño A; Hernández E; Morales E; Segura J; González E; Praga M
Kidney Int; 2002 Jan; 61(1):219-27. PubMed ID: 11786104
[TBL] [Abstract][Full Text] [Related]
35. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome.
Gulati A; Sinha A; Gupta A; Kanitkar M; Sreenivas V; Sharma J; Mantan M; Agarwal I; Dinda AK; Hari P; Bagga A
Kidney Int; 2012 Nov; 82(10):1130-5. PubMed ID: 22763815
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome: a prospective, multicenter clinical trial.
Chen W; Liu Q; Liao Y; Yang Z; Chen J; Fu J; Zhang J; Kong Y; Fu P; Lou T; Liu Z; Ji Y; Li Z; Yu X
Am J Med Sci; 2013 Feb; 345(2):81-7. PubMed ID: 22627258
[TBL] [Abstract][Full Text] [Related]
37. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy.
Zhang Q; Shi SF; Zhu L; Lv JC; Liu LJ; Chen YQ; Zhang H; Wang HY
Am J Nephrol; 2012; 35(4):312-20. PubMed ID: 22456060
[TBL] [Abstract][Full Text] [Related]
38. Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients.
Qin HZ; Liu L; Liang SS; Shi JS; Zheng CX; Hou Q; Lu YH; Le WB
BMC Nephrol; 2017 Jan; 18(1):2. PubMed ID: 28056860
[TBL] [Abstract][Full Text] [Related]
39. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
Li X; Lv R; He Q; Li H; Du X; Lin W; Li Q; He X; Wang S; Chen J
J Nephrol; 2008; 21(4):584-91. PubMed ID: 18651550
[TBL] [Abstract][Full Text] [Related]
40. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
